Novo Nordisk shares up despite missing analysts' expectations

1 February 2019
novo_nordisk_big

Danish diabetes care giant Novo Nordisk (NOV: N) this morning posted financial results that came in below expectations, but still saw the firm’s share climb 4.29% to 317.25 Danish kroner by mid-morning, boosted by a revised 2019 outlook and forecast-beating sales of its new once-weekly GLP-1 drug Ozempic (semaglutide).

Net profit for the fourth quarter of 2018 rose 3% to 8.50 billion kroner ($1.31 billion) compared to a year earlier, missing the 8.90 billion forecast by analysts in a FactSet poll. Sales rose 6.2% to 29.73 billion kroner against analysts' expectations of 29.77 billion kroner.

Full-year 2018 sales remained broadly unchanged in Danish kroner and increased by 5% in local currencies to 111.8 billion kroner.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical